华兰股份：接受银河基金等投资者调研

Core Viewpoint - Hualan Biological Engineering Co., Ltd. (SZ 301093) announced an investor meeting on November 18, 2025, where the company's Vice General Manager and Board Secretary Liu Xue participated in addressing investor inquiries [1] Financial Performance - For the first half of 2025, Hualan's revenue composition was 99.07% from the pharmaceutical manufacturing sector and 0.93% from other businesses [1] - As of the report date, Hualan's market capitalization stood at 7.7 billion yuan [1]